Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics |
RCV001213520 | SCV001385155 | uncertain significance | Gorlin syndrome; Medulloblastoma | 2019-08-23 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. This variant has not been reported in the literature in individuals with SUFU-related conditions. This variant is not present in population databases (ExAC no frequency). This sequence change replaces alanine with threonine at codon 27 of the SUFU protein (p.Ala27Thr). The alanine residue is moderately conserved and there is a small physicochemical difference between alanine and threonine. |
| Ambry Genetics | RCV002418731 | SCV002681706 | uncertain significance | Hereditary cancer-predisposing syndrome | 2021-05-22 | criteria provided, single submitter | clinical testing | The p.A27T variant (also known as c.79G>A), located in coding exon 1 of the SUFU gene, results from a G to A substitution at nucleotide position 79. The alanine at codon 27 is replaced by threonine, an amino acid with similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |